TME Pharma NV (XPAR:ALTME) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Change In Receivables?

TME Pharma NV's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means TME Pharma NV's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

TME Pharma NV's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means TME Pharma NV's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

TME Pharma NV's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TME Pharma NV's liquidation value for the six months ended in Dec. 2023 was €-0.54 Mil.

TME Pharma NV Change In Receivables Historical Data

The historical data trend for TME Pharma NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Change In Receivables Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial													-	-	-	-	-

TME Pharma NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

TME Pharma NV (XPAR:ALTME) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TME Pharma NV's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, TME Pharma NV's accounts receivable are only considered to be worth 75% of book value:

TME Pharma NV's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.245	-	2.785	+	0.75 * 0	+	0.5 * 0
=	-0.54

TME Pharma NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines